Blogs, Genomics

A Clinical Pipeline Is Not Done at VCF: The Handoffs That Still Delay a Genetic Test Result

Bioinformatician reviewing sequencing results on screen

How much of your genetic test turnaround time occurs after the VCF is generated?

For many clinical genomics labs, that is the more useful question.

The pipeline may finish overnight. Variant calls may be available before the team arrives. Yet the result may not be released until later that day or the next day.

That gap is often not a pipeline failure.

It is the time required to confirm analytical acceptance, assess reportable range, assemble current evidence, complete clinical interpretation, prepare the report, obtain authorized sign-out, and verify result delivery.

A VCF is an intermediate analytical artifact. It is not a clinical finding, a signed report, or proof that the ordering provider has received the result.

The lab cannot manage the post-VCF delay until it measures the release conditions after pipeline completion.

CAP’s NGS worksheets provide a structured framework for the clinical NGS test life cycle. The material covers validation, bioinformatics, quality management, variant interpretation, reclassification, and reanalysis. CAP’s NGS worksheet resource describes these laboratory considerations.

A clinical pipeline is complete only when the laboratory can issue a defensible, signed, delivered, and traceable result.

Connect the work that begins after the pipeline finishes.

Gate 1: The Analytical Output Must Be Accepted

A successful workflow run does not automatically mean a sample is accepted for reporting.

The laboratory still needs to review the analytical conditions that matter for the assay. These may include coverage, read depth, sample identity checks, contamination signals, control performance, variant-quality metrics, and assay-specific thresholds.

The exact requirements depend on the test and the laboratory’s validated process.

ACMG’s technical standard, Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision, provides guidance for clinical laboratories on NGS validation, quality monitoring, bioinformatics, reporting, pipeline updates, and test limitations. The ACMG technical standard states that it was developed to support validation of NGS methods and platforms, ongoing monitoring for quality results, and interpretation and reporting of identified variants.

The release record should retain:

  • Assay and panel version
  • Pipeline version
  • Reference genome build
  • Run and sample identifiers
  • Approved QC metrics
  • Exceptions and deviations
  • Reviewer or system approval
  • Reportable-range status

If the output does not meet the laboratory’s approved criteria, the VCF may still be useful for investigation. It is not automatically reportable.

Gate 2: The Variant Must Fall Within the Validated Reporting Boundary

A variant can appear in a VCF and still fall outside the laboratory’s validated reportable range.

The reason may be low coverage. It may be a difficult genomic region, a variant type outside the intended assay scope, a technical limitation, or an unresolved quality concern.

The release question is not:

Did the caller detect a variant?

It is:

Does the laboratory have enough validated evidence to report this variant for this patient, under this assay, at this time?

A defensible release record identifies the reportable-range decision and the evidence behind it. That allows the laboratory to explain whether a finding was reported, excluded, referred for confirmation, or held for review.

This is also where production teams need to distinguish between a biological finding and a reportable clinical finding. Those are not always the same thing.

Gate 3: Annotation Must Become a Reviewable Evidence Package

Annotation adds context. It may attach a gene, transcript, consequence, population frequency, database reference, literature citation, computational score, or prior classification.

Annotation does not make the clinical interpretation.

The ACMG/AMP framework uses five standard terms for sequence-variant classification. The guidelines also describe an evidence-based process for reaching those classifications. The ACMG/AMP standards and guidelines established the five-tier terminology and framework that remain widely used in clinical laboratories.

A case needs an evidence package that a qualified reviewer can understand and reconstruct later.

At minimum, it should preserve:

  • Reference sequence and transcript selection
  • Annotation sources and versions
  • Relevant population and clinical databases
  • Literature reviewed
  • Phenotype and indication context
  • Criteria applied
  • Conflicting evidence
  • Analyst observations
  • Review date

A final classification without its evidence history is difficult to defend, revisit, or amend.

Move from analytical output to structured clinical review.

Gate 4: Interpretation Requires the Right Clinical Context

The same variant can have different clinical relevance in different patients.

Phenotype, indication, inheritance pattern, family history, tumor type, treatment history, assay purpose, and prior clinical information all affect interpretation.

A VCF does not carry all of that context.

This is one of the most common reasons a case waits after pipeline completion.

The analyst may need a missing phenotype. The genetic counselor may need to clarify family history. The medical director may need more evidence. A somatic case may need treatment or biomarker context. A germline case may require segregation information or a detailed phenotype match.

The workflow needs a visible state for these cases.

“Pipeline complete” is not meaningful when the real status is:

“Clinical context required before interpretation.”

That state needs an owner, a due date, and a visible action path.

Gate 5: Interpretation Must Pass the Required Review

Clinical interpretation requires an accountable decision record.

Depending on laboratory policy and case type, review may involve an analyst, variant scientist, genetic counselor, pathologist, medical director, or second reviewer.

The workflow needs to show:

  • What was reviewed
  • Which evidence was used
  • Who approved the conclusion
  • When approval occurred
  • Whether a disagreement required escalation
  • Which findings are approved for reporting
  • Which report version reflects the decision

This is not a call to automate clinical judgment.

It is a call to make clinical judgment traceable.

A lab that cannot identify the reviewer, evidence package, approval date, and associated report version will struggle to explain how a result moved from variant call to clinical report.

The TAT Ledger Shows Where the Result Actually Waited

Pipeline runtime matters. It does not tell the full turnaround-time story.

A VCF can be available quickly while the case waits in several post-analytical queues.

Here is an illustrative release ledger:

Release eventTimeElapsed time from VCFWhat happened
VCF generated2:14 a.m.0 hoursPipeline completed successfully
Analytical QC approved8:46 a.m.6 hours 32 minutesQC review completed
Evidence package complete11:20 a.m.9 hours 6 minutesAnnotation and evidence review completed
Clinical review begins3:00 p.m.12 hours 46 minutesCase entered the clinical-review queue
Interpretation approved5:18 p.m.15 hours 4 minutesReviewer approved classification
Report signed10:12 a.m. next day31 hours 58 minutesAuthorized sign-out completed
EHR delivery confirmed10:19 a.m. next day32 hours 5 minutesResult reached the downstream system

This is an illustrative operating example, not an industry benchmark.

The purpose of the ledger is to show where a result waits. The delay may sit in evidence review, reviewer availability, report assembly, sign-out, or delivery. It may have nothing to do with compute capacity.

The useful operational metric is not only:

Pipeline runtime measures only one interval:

  1. Sample received
  2. VCF generated

Clinical turnaround time includes the next interval as well:

  1. VCF generated
  2. Clinical result delivered

The Report Is a Controlled Clinical Artifact

A clinical report is not a PDF generated at the end of a pipeline.

It is a controlled clinical artifact. It must reflect the correct test, assay version, methodology, limitations, approved findings, classification, interpretation, sign-out authority, and report version.

The report-generation workflow needs to know:

  • Which report template applies
  • Which assay version is active
  • Which findings are approved for reporting
  • Which evidence version supports the interpretation
  • Which language requires clinical approval
  • Which structured fields must be populated
  • Whether the report is original, corrected, or amended
  • Which delivery route applies

HL7’s Clinical Genomics Reporting Implementation Guide supports consistent and computable representation of genomic variants, genotypes, haplotypes, annotations, and related genomic reporting data. HL7’s Genomics Reporting Implementation Guide describes the value of sharing evolving genomic information in consistent and computable structures.

The guide does not define a laboratory’s internal review or sign-out workflow. The laboratory still needs its own approved release process.

Structured reporting does not replace clinical narrative. It gives approved data a more reliable route into EHRs, decision-support systems, research platforms, and future reanalysis workflows.

Connect approved interpretations to controlled reports and downstream result delivery.

A Signed Report Still Needs a Delivery Record

A report can be clinically approved and still fail the provider or patient workflow.

It may not reach the intended EHR. It may be routed to the wrong provider queue. It may not reconcile to the original order. It may arrive as a document without the structured data needed for downstream care. It may later be replaced by an amendment without a clear delivery history.

The release record should capture:

  • Report version
  • Release timestamp
  • Authorized signatory
  • Delivery destination
  • Delivery method
  • Delivery confirmation or acknowledgment
  • Error state and retry history
  • Relationship to the original order and accession
  • Amendment or correction status

The pipeline team cannot declare the case complete at VCF generation.

The reporting team cannot declare it complete at signature.

The delivery system cannot declare it complete only because it transmitted a message.

The laboratory needs a complete result-release record.

Five Questions for the VP Bioinformatics and Lab Director

Before investing in more compute, another annotation source, or a new reporting tool, ask:

  1. Which release gate adds the most time after VCF generation?
  2. Which post-VCF state has no named owner?
  3. Can the lab recreate the assay, pipeline, annotation, evidence, and report version for a released case?
  4. Which cases require staff to re-enter data from the VCF, review workspace, and report template?
  5. Does the lab confirm that the final report reached the intended clinical destination?

The answers often reveal that the bottleneck is not pipeline execution.

It is the clinical release chain.

Treat Post-VCF Work as a Clinical Release System

The VCF is essential. It is not the finish line.

A reliable clinical genomics workflow moves from a variant call to a signed, delivered, and traceable result without depending on manual reconstruction.

That requires:

  • Pipeline and assay version control
  • Analytical QC and reportable-range evidence
  • Versioned annotation context
  • Evidence-based clinical review
  • Named ownership of pending cases
  • Controlled report templates
  • Authorized sign-out
  • Structured and confirmed result delivery
  • An auditable release record

NonStop engineers this clinical release system across pipeline monitoring, variant analysis, interpretation, reporting, and result delivery.

StrixFlow monitors pipeline runs, identifies failures at the workflow step where they occur, tracks compute cost per sample, and sends pipeline output into the LIMS.

NonStop also engineers the workflow layers that connect analytical output to clinical review, report generation, sign-out, and downstream clinical systems.

Find the Release Gate That Is Actually Delaying Results

A pipeline replacement is not always the right first action.

Start with a sample of cases that were technically complete but clinically late.

For each case, create a simple release ledger:

Release conditionTimestampOwnerStatusDelay reason
VCF generated
Analytical QC approved
Evidence package complete
Clinical review complete
Report assembled
Sign-out complete
Delivery confirmed

This exercise reveals where work waits. It also shows whether the issue is technical, operational, clinical, or architectural.

Book a Clinical Result Release Review

NonStop’s 45-minute Architecture Review maps the workflow from analytical completion through evidence review, report generation, clinical sign-out, and result delivery.

The review identifies:

  • Pipeline-to-review handoffs that delay reportability
  • Gaps in QC, coverage, and reportable-range evidence
  • Manual work between annotation, interpretation, and report authoring
  • Missing ownership in clinical-review and sign-out queues
  • Report-template and structured-delivery constraints
  • Workflow, integration, and platform changes that reduce post-VCF delays

Frequently Asked Questions

Is a VCF a clinical genetic test result?

No. A VCF is a variant call format file that contains called variants and related information. A clinical result requires the laboratory’s validated workflow, quality criteria, reportable-range policies, interpretation process, sign-out requirements, and reporting controls.

Why does a genetic test result remain delayed after the pipeline completes?

The delay may occur in QC review, coverage assessment, evidence collection, phenotype reconciliation, variant interpretation, second review, report assembly, sign-out, or result delivery.

Pipeline runtime is only one part of total turnaround time.

What should be included in a clinical bioinformatics release record?

A release record should include assay version, pipeline version, reference genome, annotation version, run ID, sample or accession ID, QC status, reportable-range status, exceptions, reviewer approvals, and output references.

What is the difference between variant annotation and variant interpretation?

Annotation adds information to a variant, such as gene, transcript, population frequency, consequence, and database references.

Interpretation applies clinical evidence and laboratory policy to determine the classification and relevance of the variant for a specific patient and test context.

What does reportable range mean in clinical genomics?

Reportable range is the portion of an assay for which the laboratory has validated its ability to detect and report specified variant types under defined conditions.

A variant can appear in a VCF but still fall outside the assay’s validated reportable range or quality requirements.

How can a laboratory reduce post-VCF turnaround-time delays?

Track the timestamps and ownership of every release condition after pipeline completion. This includes QC approval, evidence completion, clinical review, report assembly, sign-out, and delivery confirmation.

Target the release gate that creates the largest and most frequent delay.